Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 19/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074472 | 1.00 | MAP4K4 (0.51) | MAP4K4PRKCDMINK1S1PR1S1PR3 | |
| SCHEMBL3095824 | 0.94 | S1PR1 (0.51) | MAP4K4PRKCDMINK1S1PR1S1PR3 | |
| SCHEMBL3088258 | 0.88 | S1PR1 (0.63) | S1PR1S1PR3 | |
| SCHEMBL3088264 | 0.88 | S1PR1 (0.63) | S1PR1S1PR3 | |
| SCHEMBL3090122 | 0.85 | S1PR1 (0.47) | MAP4K4PRKCDMINK1S1PR1S1PR3 | |
| SCHEMBL3080674 | 0.85 | S1PR1 (0.47) | MAP4K4PRKCDMINK1S1PR1S1PR3 | |
| SCHEMBL3092745 | 0.84 | S1PR1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL3087173 | 0.83 | S1PR1 (0.54) | S1PR1S1PR3 | |
| SCHEMBL3095687 | 0.81 | S1PR1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL3662496 | 0.81 | S1PR1 (0.53) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8299086-B2 | Pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2217594-A2 | NOVEL PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | MAP4K4 2095/4885PRKCD 2562/4885MINK1 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.